First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e006127
DOI: 10.1136/jitc-2022-006127 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.02.2023. Verfasst von Neal E Ready und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University, Durham, North Carolina, USA neal.ready@duke.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, HIV Infections, Lung Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Bristol Myers Squibb.
Abstract (Originalsprache)
Background
CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1 (cohort A) and special populations (cohort A1: ECOG PS 2; or ECOG PS 0–1 with untreated brain metastases, renal impairment, hepatic impairment, or controlled HIV infection).
Methods
Cohorts A and A1 received nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks. The primary endpoint was the incidence of grade 3–4 and grade 5 immune-mediated adverse events (IMAEs; adverse events (AEs) deemed potentially immune-related, occurring
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Duke University, Durham, North Carolina, USA neal.ready@duke.edu.
- Division of Pneumo-Oncology, Hôpital Sainte Musse, Toulon, Provence-Alpes-Côte d'Azur, France.
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- Department of Oncology, Oncology Institute Prof Dr Ion Chiricuta, Cluj-Napoca, Romania.
- University of Medicine and Pharmacy Iuliu Hațieganu, Cluj-Napoca, Romania.
ORCID-Profile: Neal E Ready
Förderung
- NCI NIH HHS
- Bristol Myers Squibb
Zitieren
APA
Ready, N. E., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T. E., Rosario García Campelo, M., Jao, K., Barlesi, F., Bordenave, S., Rijavec, E., Urban, L., Aucoin, J. S., Zannori, C., Vermaelen, K., Arén Frontera, O., Curioni Fontecedro, A., Sánchez-Gastaldo, A., Juan-Vidal, O., Linardou, H., …, & Paz-Ares, L. (2023). First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. Journal for ImmunoTherapy of Cancer, 11(2), e006127. https://doi.org/10.1136/jitc-2022-006127
Vancouver
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, et al. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. Journal for ImmunoTherapy of Cancer. 2023;11(2):e006127. doi:10.1136/jitc-2022-006127
BibTeX
@article{Ready2023,
author = {Ready, Neal E and Audigier-Valette, Clarisse and Goldman, Jonathan W and Felip, Enriqueta and Ciuleanu, Tudor-Eliade and Rosario García Campelo, María and Jao, Kevin and Barlesi, Fabrice and Bordenave, Stéphanie and Rijavec, Erika and Urban, Laszlo and Aucoin, Jean-Sébastien and Zannori, Cristina and Vermaelen, Karim and Arén Frontera, Osvaldo and Curioni Fontecedro, Alessandra and Sánchez-Gastaldo, Amparo and Juan-Vidal, Oscar and Linardou, Helena and Poddubskaya, Elena and Spigel, David R and Ahmed, Samreen and Maio, Michele and Li, Sunney and Chang, Han and Fiore, Joseph and Acevedo, Angelic and Paz-Ares, Luis},
title = {First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {2},
pages = {e006127},
doi = {10.1136/jitc-2022-006127}
}
EUVIMED